Drug Discovery 2014
Print Print
Presentation
Tue 2 September
3 September
DAY 1Charter 1Charter 2Charter 3Charter 4Exhibition - Central Hall 1
DAY 2
DAY 1Charter 1Charter 2Charter 3Charter 4Exhibition - Central Hall 1
DAY 2
9:00 9:00:
9:05: 9:05:
9:10: Innovations in Screening & Assay Development
Chairs: Alan Wise, TPP, UK
Ryan Bingham, GSK,
Phenotypic Discovery & Cellular Imaging
Chairs: Marc Bickle, MaxPlanck  Christian Parker, Novartis  		 Oncology Drug Discovery
Chairs: John Hickman, AGON Consulting  Namir Hassan, Immunocore  		 Core Technologies Forum
09:10 (5 mins)
Core Technologies, Forum  
 9:10:
9:15: High-Throughput Screening - Challenges & Opportunities
09:15 (45 mins)
Keynote Speaker: Lorenz Mayr, AstraZeneca  
 Phenotypic assays in drug discovery
09:15 (45 mins)
Keynote Speaker: Daniela Gabriel, Novartis Institutes for BioMedical Research  
 Systems medicine in acute myeloid leukemia (AML) and beyond
09:15 (45 mins)
Keynote Speaker: Olli Kallioniemi, Institute for Molecular Medicine Finland (FIMM)  
 Sample Management - Is a fully integrated sample management capability the future?
Chairs: Clive Green, Astra Zeneca,
9:15:
9:20: 9:20:
9:25: 9:25:
9:30: Process software applications at Titian
09:30 (15 mins)
Toby Winchester, Titian Software  
 9:30:
9:35: 9:35:
9:40: 9:40:
9:45: Research and biobanking at the Nottingham Health Science Biobank
09:45 (15 mins)
Balwir Matharoo-Ball, Nottingham University Hospital  
 9:45:
9:50: 9:50:
9:55: 9:55:
10:00 Flow cytometry as a drug screening platform
10:00 (30 mins)
Rob Jepras, GSK  
 Three-dimensional imaging of spheroids and tissues with light sheet-based fluorescence microscopy (LSFM, DSLM, SPIM)
10:00 (30 mins)
Ernst Stelzer, Goethe Universitat Frankfurt am Main  
 Circulating Tumour Cells (CTCs) in Lung Cancer - biology, biomarkers and mouse models
10:00 (30 mins)
Caroline Dive, CRUK Manchester Institute  
 Healthcare, pharmaceutical and biotechnology sectors
10:00 (15 mins)
James Craven, TTP Labtech  
 10:00
10:05 10:05
10:10 10:10
10:15 Specialized biological sample and material management
10:15 (15 mins)
David Wilson, Fisher Bioservices  
 10:15
10:20 10:20
10:25 10:25
10:30 Coffee Break 10:30
10:35 10:35
10:40 10:40
10:45 10:45
10:50 10:50
10:55 10:55
11:00 Structure based GPCR drug discovery
11:00 (30 mins)
Alastair Brown, Heptares Therapeutics Ltd  
 High Throughput/High Content Screen to Identify Modulators of Neutrophil Extracellular Trap (NET) Formation
11:00 (30 mins)
Axel Choidas, Lead Discovery Center GmbH  
 PREDECT - A European PPP to improve predictability of pre-clinical models
11:00 (30 mins)
Ralph Graeser, Janssen  
 Innovative Automation - What can we automate next ?
Chairs: Malcolm Crook,
11:00
11:05 11:05
11:10 11:10
11:15 Management of system & IT requirements for new automation projects
11:15 (25 mins)
Jonathan Wingfield, AstraZeneca  
 11:15
11:20 11:20
11:25 11:25
11:30 Poster Taster Talks Poster Taster Talks Poster Taster Talks 11:30
11:35 Flow Cytometry FRET for the autmatic & fast detection of protein interatctions
11:35 (10 mins)
Kerstin von Kolontaj, Miltenyi Biotec Gmbh  
 Establishing a National Phenotypic Screening Centre in the UK
11:35 (10 mins)
Paul Andrews, Stem Cell Solutions   
 Use of DNA repair Cell Based Assays to Determine Efficacy of ERCC1 Inhibitor Compounds
11:35 (10 mins)
Laura Stennett, MRCT  
 11:35
11:40 Specifying new equipment and robots for automation systems
11:40 (25 mins)
Roger Northwood, Unilever  
 11:40
11:45 Screening for novel inhibitors of thymidylate synthase (TS) using CETSA
11:45 (15 mins)
Helena Almqvist, Karolinska Institute   
 Side by Side: an evaluation of 2D vs 3D Cell Culture plates
11:45 (15 mins)
Sophie Quick, AstraZeneca  
 Glycolysis as a promising target for Breast & Ovarian cancer treatment
11:45 (15 mins)
Chrysi Xintaropoulou, University of Edinburgh  
 11:45
11:50 11:50
11:55 11:55
12:00 Snapshot Presentations Snapshot Presentations Snapshot Presentations 12:00
12:05 Software requirements of new automation systems
12:05 (25 mins)
Rob Harkness, Labapps  
 12:05
12:10 12:10
12:15 12:15
12:20 12:20
12:25 12:25
12:30 Safety DMPK Screening (Lunch Provided during session)
Chairs: Andrew Brown, GlaxoSmithKline,
Lunch, Exhibition, Poster viewing 12:30
12:35 12:35
12:40 Co-chair
12:40 (5 mins)
Joanne Bowes, AstraZeneca  
 12:40
12:45 Discussion Leaders
12:45 (25 mins)
Stephen Brough, GlaxoSmithKline  
 12:45
12:50 12:50
12:55 12:55
1:00 PerkinElmer Workshop in Exchange 10 Tecan Workshop in Exchange 8 1:00:
1:05: 1:05:
1:10: Discussion Leaders
13:10 (25 mins)
Helen Garside, AstraZeneca  
 1:10:
1:15: 1:15:
1:20: 1:20:
1:25: 1:25:
1:30: 1:30:
1:35: Discussion Leaders
13:35 (20 mins)
Tim Smith, Cyprotex  
 1:35:
1:40: 1:40:
1:45: 1:45:
1:50: 1:50:
1:55: Welcome from the ELRIG Chairman
13:55 (5 mins)
Sanj Kumar, ELRIG & DiscoverX  
 1:55:
2:00 Introduction to Plenary Keynote
14:00 (5 mins)
Peter Simpson, AstraZeneca  
 Plenary Speaker Plenary Speaker Plenary Speaker 2:00:
2:05: Genetic drivers of cancer growth and resistance mechanisms
14:05 (55 mins)
Keynote Speaker: Susan Galbraith, AstraZeneca  
 2:05:
2:10: 2:10:
2:15: 2:15:
2:20: 2:20:
2:25: 2:25:
2:30: 2:30:
2:35: 2:35:
2:40: 2:40:
2:45: 2:45:
2:50: 2:50:
2:55: 2:55:
3:00 Primarily primary and then 3D: A full deck phenotypic HTS on primary calls and evaluation of 3D culture applications for secondary screening
15:00 (30 mins)
Ingo Kober, Merck Serono  
 Drug Discovery for Human African Trypanosomiasis: Target-Based and Phenotypic Approaches
15:00 (30 mins)
Ian Gilbert, University of Dundee  
 Shaping the immune contexture in human cancer
15:00 (30 mins)
Wolf H Fridman, University Paris-Descartes  
 Complex, High Content and Biologics data
Chairs: Joe Bradley, Scitegrity,
David Lee, UCB,
Mark Roberts, Tessella,
3:00:
3:05: 3:05:
3:10: 3:10:
3:15: Complex Data
15:15 (15 mins)
Andy Vines, IDBS  
 3:15:
3:20: 3:20:
3:25: 3:25:
3:30: Adhirons - novel tools for drug discovery
15:30 (30 mins)
Darren Tomlinson, University of Leeds  
 Utilisation of cell models from patient-derived iPSCs to further understand Parkinson's Disease
15:30 (30 mins)
Ann Macdonald, Thermo Fisher Scientific  
 Immune Mediated Therapy for Cancer: Preclinical Assessment of Immunobiology and Combination Activity in vitro and in vivo
15:30 (30 mins)
Robert Wilkinson, MedImmune  
 Complex Data
15:30 (15 mins)
Stephan Heyse, Genedata  
 3:30:
3:35: 3:35:
3:40: 3:40:
3:45: Complex Data
15:45 (15 mins)
Roland Knispel, ChemAxon - HELM Project  
 3:45:
3:50: 3:50:
3:55: 3:55:
4:00 Mass Spectrometry in the Hit to Lead phase of drug discovery: Applications today and options for tomorrow
16:00 (30 mins)
Jonathan Wingfield, AstraZeneca  
 Phenotypic discovery in AstraZeneca
16:00 (30 mins)
Anna Collen, AstraZeneca  
 ImmTACs: Bi-specific TCR-anti-CD3 fusions for potent redirected killing of cancer cells
16:00 (30 mins)
Joseph Dukes, Immunocore Ltd  
 Complex Data
16:00 (15 mins)
Geoff Holdgate, AstraZeneca  
 4:00:
4:05: 4:05:
4:10: 4:10:
4:15: Complex Data
16:15 (15 mins)
Janette Phi, IntelliCyt  
 4:15:
4:20: 4:20:
4:25: 4:25:
4:30: Complex Data
16:30 (15 mins)
Dermott O'Callaghan, TRN  
 Poster Viewing 4:30:
4:35: 4:35:
4:40: 4:40:
4:45: 4:45:
4:50: 4:50:
4:55: 4:55:
5:00 5:00:
5:05: 5:05:
5:10: 5:10:
5:15: 5:15:
5:20: 5:20:
5:25: 5:25:
5:30: Drinks Reception 5:30:
5:35: 5:35:
5:40: 5:40:
5:45: 5:45:
5:50: 5:50:
5:55: 5:55:
6:00 6:00: